Nestlé is beating a retreat from topical dermatology drug R&D at the cost of up to 450 jobs and possibly a facility.
Andrew Witty jumped into biotech venture capital, Aerie poached another exec from Alcon, Roivant tapped Silicon Valley vet to run trial AI company.
For pharma and biotech, in which data is the most valuable asset, industry analysts agree that digital transformation presents an opportunity to realize…
With some tweaks, a gene therapy delivered to the liver could become a new treatment for multiple sclerosis.
The decision positions the Celgene-backed cancer immunotherapy biotech to move oral small molecule FLX475 into the clinic later this year.
After a $28 million financing, Provention Bio has grabbed two IBD candidates from Janssen that should make it a double clinical-stage biotech in 2018.
Indivumed and Helomics have teamed up to advance research in personalized cancer treatments.
The new "Vant" added to the Vivek Ramaswamy family, with its aim of improving trials with artificial intelligence, announced its new CEO this week.
The startup has secured the support of the ex-Sarepta CEO’s Xontogeny and $10 million to take a LANCL2-targeted IBD drug into the clinic.
Researchers at Duke University developing a glioblastoma treatment based on poliovirus are unraveling the process by which the virus fights malignancy.
Researchers at Sanofi and the NIH have published preclinical evidence showing that a three-pronged approach may prevent HIV in healthy people.